I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING FILED VIA THE

(b) 

ELECTRONIC FILING SYSTEM, ON:								
January 8, 2009								
		J. Galo/	1		January 8, 2009			
SIGNATURE DATE  IN THE UNITED STATES PATENT AND TRADEMARK OFFICE								
Applicants				:	Zee UPTON et al.			
Serial No.				:	10/565,616			
Filing Date				:	June 9, 2006			
For				:	SKIN REGENERATION SYSTEM			
Confirmation No.				:	2998			
Group Art Unit				:	1632			
Examiner				:	Magdalene K. Sgagias			
Attorn	ey Do	cket		:	FAK-8011			
Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450								
			INFORMATION	DISCLOS	URE STATEMENT			
Sir: 1.								
2.	Regarding each listed document that is not in the English language, an English-language translation accompanies this Statement as indicated on the attached PTO-1449 or a corresponding U.S. Patent is enclosed, or an English abstract, or a concise explanation of the relevance of the document is set forth on an attached sheet.							
3.	Pursuant to 37 CFR §1.97(b) this Statement is being filed (one must be checked):							
	(a)		Within three mo					

Before the mailing date of a first Office

Action on the merits.

but before the mailing date		efore th ance or	iod set forth in 37 CFR §1.97(b) e mailling date of either a final action or a notice of an action that otherwise closes prosecution in the		
			1)		A certification is given below,
			2)		Enclosed is a check covering the fee (\$180.00) set forth in §1.17(p) for consideration of this Statement, or
			3)		Charge the fee set forth in 37 CFR §1.17(p) to Deposit Account No. 20-0090.
			4)		Charge the fee set forth in 37 CFR §1.17(p) to the Credit Card as shown on the attached Credit Card information authorization form PTO-2038.
			r a notice of allowance, but before payment fee. The required certification and fee is		
			1)		Enclosed is a check covering the fee set forth in 37 CFR §1.17(p) \$180, or
			2)		Charge the fee set forth in 37 CFR §1.17(p) to Deposit Account No. 20-0090.
			3)		Charge the fee set forth in 37 CFR §1.17(p) to the Credit Card as shown on the attached Credit Card information authorization form PTO-2038.
	Certif	ication	(if appl	licable)	:
	(a)		each first c office	item of ited in a in a co	gned hereby certifies that information contained in this Statement was any communication from a foreign patent unterpart foreign application not more than s prior to the filing of this Statement.

4.

(b)		The undersigned hereby certifies that
. ,	_	no item of information contained in this Statement was
		cited in a communication from a foreign patent office in a
		counterpart foreign application, and, to the undersigned's
		knowledge after making reasonable inquiry no item of
		information contained in the Statement, was known to
		any individual designated in 37 CFR §1.56(c) more than
		three months prior to the filing of this Statement.

- The Commissioner is hereby authorized to charge any additional fees, fees underpaid, or credit any overpayment with regard to this Statement to Deposit Account No. 20-0090.
- Concise Explanation (if needed):
  - (1) Below is a Concise Statement of Relevance of enclosed non-English language document(s).

## FOREIGN PATENT DOCUMENTS

Patent No.	<u>Relevance</u>
PCT WO 2002/024219 A1	In English.

## OTHER DOCUMENTS

Noble et al.,2003 "Insulin-Like Growth Factor-II Bound to Vitronectin Enhances MCF-7 Breast Cancer Cell Migration", *Endocrinology*, 144:2417-2424.

Kricker et al. 2003 "Structural and Functional Evidence for the Interaction of Insulin-Like Growth Factors (IGFs) and IGF Binding Proteins with Vitronectin", Endocriblow, 144:2807-2815.

Tsuboi et al. 1992 "Stimulation of Keratinocyte Migration by Growth Factors", *The Journal of Determatology*, 19:652-653.

O'Keefe et al. 1988 "Stimulation of Growth of Keratinocytes by Basic Fibroblast Growth Factor", *J. Invest. Dermatol*, 90:767-769.

Ando et al. 1993 "Epidermal Growth Factor and Insulin-Like Growth Factor I Enhance Keratinocyte Migration", *J. Invest. Dermatol.*, 100:633-639.

Bhora et al., 1995, "Effect of Growth Factors on Cell Proliferation and Epithelialization in Human Skin", *J. Surg. Res.* 59:236-244.

Krane et al., 1991, "Synergistic Effects of Epidermal Growth Factor (EGF) and Insulin-Like Growth Factor I/Somatomedin C. (IGF-I) on Keratinocyte Proliferation May Be Mediated by IGF-I Transmodulation of the EGF Receiptor", *J. Invest. Dermatol*, 96:419-424.

## OTHER DOCUMENTS

Nam et al., 2002, "Vitronectin Binding to IGF Binding Protein-5 (IGFBP-5) Alters IGFBP-5 Modulation of IGF-I Actions". *Endocrinology*, 143:30-36.

Schleicher et al., 2005, "Surface Modification by Complexes of Vitronectin and Growth Factors for Serum-Free Culture of Human Osteoblasts", *Tissue Engineering*, 11:1688-1698.

Warwick et al., 2002, "The Co-Application of Sprayed Cultured Autologous Keratinocytes and Autologous Fibrin Sealant in a Porcine Wound Model", *British Journal of Plastic Surgery*, 55:219-227.

Nagano et al., 1992, "Yolk Vitronectin", *The Journal of Biological Chemistry*, 267:24863-24870.

Seger et al., 1998, "Phosphorylation of Vitronectin by Casein Kinase II", *The Journal of Biological Chemistry*, 273:24805-24813.

Respectfully submitted,

## /Richard S. Wesorick/

Richard S. Wesorick Reg. No. 40,871

TAROLLI, SUNDHEIM, COVELL, & TUMMINO L.L.P. 1300 East Ninth Street, Suite 1700 Cleveland, OH 44114 Phone: (216) 621-2234

Fax: (216) 621-4072 Customer No.: 26,294